Heron Therapeutics, Inc. - Common Stock (HRTX)
Frequently Asked Questions About Heron Therapeutics, Inc. - Common Stock (HRTX)
Has Heron Therapeutics partnered with other companies?
Yes, Heron Therapeutics has engaged in strategic partnerships and collaborations with various pharmaceutical companies and research institutions. These alliances aim to enhance product development, marketing, and distribution capabilities, as well as to expand their innovative portfolio.
How does Heron Therapeutics handle collaborations with healthcare professionals?
Heron Therapeutics actively collaborates with healthcare professionals through educational programs, advisory boards, and clinical trials. These interactions allow the company to gain invaluable insights into patient needs and treatment barriers, fostering a collaborative environment conducive to innovation and improved patient care.
How does SUSTOL work?
SUSTOL is a long-acting injectable formulation of granisetron that provides prolonged control of nausea and vomiting associated with chemotherapy. It works by blocking serotonin receptors in the brain that trigger the vomiting reflex, ensuring patients have a more manageable experience during and after their chemotherapy treatment.
Is Heron Therapeutics publicly traded?
Yes, Heron Therapeutics, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol HRTX. The company became publicly listed in 2014, allowing investors to participate in its growth and development.
What are Heron’s clinical trial focuses?
Heron Therapeutics focuses on conducting clinical trials that evaluate the safety and efficacy of its drug candidates in the areas of oncology, postoperative care, and pain management. These trials play a critical role in advancing their pipeline and ensuring that their products meet regulatory standards for patient use.
What are the key products of Heron Therapeutics?
Heron Therapeutics has several significant products, including CINVANTI (aprepitant) injection, which is used for the prevention of chemotherapy-induced nausea and vomiting. The company is also known for SUSTOL, a long-acting formulation of granisetron, used for the same purpose, and has additional products in its pipeline targeting various therapeutic areas.
What are the major challenges faced by Heron Therapeutics?
Like many biopharmaceutical companies, Heron Therapeutics faces several challenges, including navigating a complex regulatory environment, competition from other pharmaceutical companies, and the need to maintain a robust pipeline of products. These challenges necessitate strategic planning and continuous innovation to ensure success.
What distinguishes Heron Therapeutics in the biopharmaceutical industry?
What distinguishes Heron Therapeutics in the biopharmaceutical industry is its focus on unmet medical needs, innovative drug formulations, and a commitment to improving patient care. Through the integration of advanced delivery systems and a patient-centered approach, Heron aims to provide solutions that enhance the treatment experience.
What does Heron Therapeutics, Inc. do?
Heron Therapeutics, Inc. is a biopharmaceutical company that focuses on developing and commercializing innovative and differentiated products to address unmet medical needs in the fields of pain management and postoperative nausea and vomiting. The company primarily aims to improve patient outcomes through targeted therapies and novel formulations.
What is CINVANTI?
CINVANTI is one of Heron Therapeutics' flagship products, a proprietary injectable formulation of aprepitant, approved for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. It is notable for its unique formulation that allows for intravenous administration.
What is Heron Therapeutics' vision for the future?
Heron Therapeutics' vision for the future is to be a leader in developing innovative therapies that significantly improve patient outcomes in pain management and nausea prevention. The company aims to expand its market presence, advance its product portfolio, and continue to address unmet medical needs in evolving therapeutic areas.
What is Heron’s approach to patient safety?
Heron Therapeutics places a strong emphasis on patient safety, implementing rigorous clinical trial protocols and conducting post-marketing studies to monitor the safety and efficacy of its products. The company adheres to high ethical standards and regulatory requirements to ensure that patient health and safety are always prioritized.
What is the company's mission?
Heron Therapeutics' mission is to improve the lives of patients by developing innovative products that offer significant advances in pain management and the prevention of nausea and vomiting. The company is dedicated to addressing unmet medical needs through science and transformative therapies, ensuring better health outcomes.
What research and development efforts does Heron Therapeutics have?
Heron Therapeutics is deeply committed to research and development (R&D), focusing on creating innovative therapeutic solutions. The company's R&D pipeline includes multiple candidates addressing various aspects of pain management, postoperative nausea, and potential new therapeutic areas, leveraging advanced drug delivery technologies to enhance patient outcomes.
When was Heron Therapeutics founded?
Heron Therapeutics was founded in 1983 and has since evolved into a prominent player in the biopharmaceutical industry, focusing on innovative therapies that significantly enhance patient care and quality of life.
Where is Heron Therapeutics headquartered?
Heron Therapeutics is headquartered in San Diego, California. The location provides access to a rich ecosystem of biotechnology and pharmaceutical companies, research institutions, and talent.
Who are Heron Therapeutics' target customers?
Heron Therapeutics primarily targets healthcare providers, including hospitals, oncologists, and anesthesiologists, as well as patients undergoing treatment for cancer and those requiring pain management solutions. The company's products are designed to meet the needs of these groups effectively.
Who are the key executives at Heron Therapeutics?
Heron Therapeutics is led by a team of experienced executives in the biopharmaceutical industry. Key executives include the CEO, President, and other senior leaders who bring extensive knowledge in drug development, commercialization, and business strategy, driving the company toward its mission and goals.
What is the current price of Heron Therapeutics, Inc. - Common Stock?
The current price of Heron Therapeutics, Inc. - Common Stock is 2.230
When was Heron Therapeutics, Inc. - Common Stock last traded?
The last trade of Heron Therapeutics, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Heron Therapeutics, Inc. - Common Stock?
The market capitalization of Heron Therapeutics, Inc. - Common Stock is 313.89M
How many shares of Heron Therapeutics, Inc. - Common Stock are outstanding?
Heron Therapeutics, Inc. - Common Stock has 140.76M shares outstanding.